Visudyne (Verteporfin) - Summary

VISUDYNE SUMMARY

VISUDYNE^®
(VERTEPORFIN FOR INJECTION)
CC#34077 revises 05-Jul-05

VISUDYNE® (verteporfin for injection) is a light activated drug used in photodynamic therapy.

VISUDYNE therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

There is insufficient evidence to indicate VISUDYNE for the treatment of predominantly occult subfoveal choroidal neovascularization.

See all Visudyne indications & dosage >>

VISUDYNE NEWS HIGHLIGHTS

Published Studies Related to Visudyne (Verteporfin)

Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. [2008.10]

Half-Dose Verteporfin Photodynamic Therapy for Acute Central Serous Chorioretinopathy One-Year Results of a Randomized Controlled Trial. [2008.06.04]

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. [2008.05]

Randomized multicenter trial of more intense and standard early verteporfin treatment of neovascular age-related macular degeneration. [2008.01]

Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. [2007.12]

more >>

Clinical Trials Related to Visudyne (Verteporfin)

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD) [Terminated]

Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) [Active, not recruiting]

Visudyne® in Occult (VIO) [Completed]

VERITAS: A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib [Active, not recruiting]

Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration [Completed]

more >>